Your browser doesn't support javascript.
loading
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page, Elizabeth C; Bancroft, Elizabeth K; Brook, Mark N; Assel, Melissa; Hassan Al Battat, Mona; Thomas, Sarah; Taylor, Natalie; Chamberlain, Anthony; Pope, Jennifer; Raghallaigh, Holly Ni; Evans, D Gareth; Rothwell, Jeanette; Maehle, Lovise; Grindedal, Eli Marie; James, Paul; Mascarenhas, Lyon; McKinley, Joanne; Side, Lucy; Thomas, Tessy; van Asperen, Christi; Vasen, Hans; Kiemeney, Lambertus A; Ringelberg, Janneke; Jensen, Thomas Dyrsø; Osther, Palle J S; Helfand, Brian T; Genova, Elena; Oldenburg, Rogier A; Cybulski, Cezary; Wokolorczyk, Dominika; Ong, Kai-Ren; Huber, Camilla; Lam, Jimmy; Taylor, Louise; Salinas, Monica; Feliubadaló, Lidia; Oosterwijk, Jan C; van Zelst-Stams, Wendy; Cook, Jackie; Rosario, Derek J; Domchek, Susan; Powers, Jacquelyn; Buys, Saundra; O'Toole, Karen; Ausems, Margreet G E M; Schmutzler, Rita K; Rhiem, Kerstin; Izatt, Louise; Tripathi, Vishakha; Teixeira, Manuel R.
Affiliation
  • Page EC; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Bancroft EK; Oncogenetics Team, Institute of Cancer Research, London, UK; Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Brook MN; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Assel M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, USA.
  • Hassan Al Battat M; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Thomas S; Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Taylor N; Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Chamberlain A; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Pope J; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Raghallaigh HN; Oncogenetics Team, Institute of Cancer Research, London, UK.
  • Evans DG; Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Rothwell J; Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Maehle L; Department of medical genetics, Oslo University Hospital, 0424 Oslo, Norway.
  • Grindedal EM; Department of medical genetics, Oslo University Hospital, 0424 Oslo, Norway.
  • James P; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia; Genetic Medicine, The Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Mascarenhas L; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • McKinley J; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Side L; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
  • Thomas T; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
  • van Asperen C; Leiden University Medical Center, Leiden, The Netherlands.
  • Vasen H; The Foundation for the Detection of Hereditary Cancer, Leiden, The Netherlands.
  • Kiemeney LA; Radboud University Medical Center, Nijmegen, The Netherlands.
  • Ringelberg J; The Foundation for the Detection of Hereditary Cancer, Leiden, The Netherlands.
  • Jensen TD; Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
  • Osther PJS; Department of Urology, Vejle Hospital, Vejle, Denmark.
  • Helfand BT; John and Carol Walter Center for Urological Health, Division of Urology, NorthShore University HealthSystem, Evanston, IL, USA.
  • Genova E; John and Carol Walter Center for Urological Health, Division of Urology, NorthShore University HealthSystem, Evanston, IL, USA.
  • Oldenburg RA; Department of clinical genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Cybulski C; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Wokolorczyk D; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Ong KR; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
  • Huber C; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
  • Lam J; Department of Urology, Flinders Medical Centre, Bedford Park, SA, Australia.
  • Taylor L; Department of Urology, Repatriation General Hospital, Daw Park, SA, Australia.
  • Salinas M; Hereditary Cancer Program, ICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC, Barcelona, Spain.
  • Feliubadaló L; Hereditary Cancer Program, ICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC, Barcelona, Spain.
  • Oosterwijk JC; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • van Zelst-Stams W; Radboud University Medical Center, Nijmegen, The Netherlands.
  • Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
  • Rosario DJ; Royal Hallamshire Hospital, Sheffield, UK.
  • Domchek S; Basser Research Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Powers J; Basser Research Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Buys S; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • O'Toole K; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Ausems MGEM; Division of Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Centre, Utrecht, The Netherlands.
  • Schmutzler RK; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Rhiem K; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Izatt L; Clinical Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Tripathi V; Clinical Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Teixeira MR; Genetics Department and Research Center, Portuguese Oncology Institute (IPO Porto), Porto, Portugal; Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal.
Eur Urol ; 76(6): 831-842, 2019 12.
Article in En | MEDLINE | ID: mdl-31537406
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Germ-Line Mutation / Genes, BRCA1 / Genes, BRCA2 / Early Detection of Cancer / Genetic Carrier Screening Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2019 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Germ-Line Mutation / Genes, BRCA1 / Genes, BRCA2 / Early Detection of Cancer / Genetic Carrier Screening Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Adult / Aged / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2019 Type: Article Affiliation country: United kingdom